Equillium to Present at the SVB Leerink Virtual Global Healthcare Conference

Rhea-AI Summary

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, announced its participation in the SVB Leerink Virtual Global Healthcare Conference from February 14-18, 2022. Chief Executive Officer Bruce Steel and Chief Scientific Officer Steve Connelly will present an overview of the company and its clinical programs on February 16 at 2:20 PM ET. Attendees can join via a live webcast on Equillium's website, with an archived version available for 90 days. Equillium focuses on developing itolizumab for severe autoimmune disorders with significant unmet needs.

LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in a fireside chat presentation at the SVB Leerink Virtual Global Healthcare Conference, taking place February 14 – 18, 2022.

Bruce Steel, Equillium’s chief executive officer, and Steve Connelly Ph.D., Equillium’s chief scientific officer, will provide a high-level overview of the company and ongoing clinical programs. Mr. Steel, Dr. Connelly and other members of Equillium’s leadership team will be available for one-on-one meetings during the conference.

Date:		Wednesday, February 16, 2022
Time:		2:20 PM Eastern Time | 11:20 AM Pacific Time
Location:		Virtual Webcast

A live webcast of the presentation will be available under the “Investors” section of the Company’s website at https://ir.equilliumbio.com/events-and-presentations. An archived replay will be available for 90 days.

About Equillium

Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD) and lupus/lupus nephritis.

For more information, visit www.equilliumbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220209005390/en/

Investor Contact

Michael Moore

Vice President, Investor Relations & Corporate Communications

619-302-4431

ir@equilliumbio.com

Media Contacts

Aljanae Reynolds

Wheelhouse Life Science Advisors

areynolds@wheelhouselsa.com

Source: Equillium, Inc.

FAQ

What is Equillium's participation in the SVB Leerink Conference 2022?

Equillium will participate in the SVB Leerink Virtual Global Healthcare Conference from February 14-18, 2022.

When is Equillium's presentation at the conference?

Equillium's presentation is scheduled for February 16, 2022, at 2:20 PM ET.

Who will represent Equillium at the conference?

CEO Bruce Steel and CSO Steve Connelly will represent Equillium at the conference.

How can I watch Equillium's presentation?

The presentation will be available via a live webcast on Equillium's website.

What is the focus of Equillium's research?

Equillium is developing itolizumab for severe autoimmune and inflammatory disorders with high unmet medical needs.